Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders
- PMID: 12372277
- DOI: 10.1016/s0896-6273(02)00872-3
Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders
Abstract
The mechanisms of neurodegeneration in the CAG repeat polyglutamine diseases, including Spinal and Bulbar Muscular Atrophy (SBMA), Huntington's disease (HD), DentatoRubral and PallidoLuysian Atrophy (DRPLA), and Spino-Cerebellar Ataxia (SCA), have been controversial. Issues have included the role of polyglutamine aggregation and possible amyloid formation, localization in the cell nucleus, and possible proteolytic processing. Proposed mechanisms have included activation of caspases or other triggers of apoptosis, mitochondrial or metabolic toxicity, and interference with gene transcription. Recent studies using transgenic mouse and Drosophila models have helped resolve some of these issues and raise hopes for development of therapeutic targets.
Similar articles
-
Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.ACS Chem Neurosci. 2024 Aug 7;15(15):2665-2694. doi: 10.1021/acschemneuro.4c00184. Epub 2024 Jul 12. ACS Chem Neurosci. 2024. PMID: 38996083 Free PMC article. Review.
-
[Molecular biology of polyglutamine diseases].Postepy Hig Med Dosw. 2002;56(6):779-88. Postepy Hig Med Dosw. 2002. PMID: 12661407 Review. Polish.
-
[The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].Mol Biol (Mosk). 2019 Nov-Dec;53(6):954-967. doi: 10.1134/S002689841906003X. Mol Biol (Mosk). 2019. PMID: 31876275 Review. Russian.
-
Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.Biol Chem. 2000 Sep-Oct;381(9-10):937-42. doi: 10.1515/BC.2000.114. Biol Chem. 2000. PMID: 11076024 Review.
-
The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology.Handb Clin Neurol. 2018;147:143-170. doi: 10.1016/B978-0-444-63233-3.00011-7. Handb Clin Neurol. 2018. PMID: 29325609 Review.
Cited by
-
Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response.J Mol Med (Berl). 2007 Dec;85(12):1421-8. doi: 10.1007/s00109-007-0251-9. Epub 2007 Oct 18. J Mol Med (Berl). 2007. PMID: 17943263 Free PMC article.
-
Invertebrate models of neurologic disease: insights into pathogenesis and therapy.Curr Neurol Neurosci Rep. 2003 Sep;3(5):442-8. doi: 10.1007/s11910-003-0028-7. Curr Neurol Neurosci Rep. 2003. PMID: 12914688 Review.
-
A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease.Mol Ther Nucleic Acids. 2022 May 5;28:702-715. doi: 10.1016/j.omtn.2022.04.031. eCollection 2022 Jun 14. Mol Ther Nucleic Acids. 2022. PMID: 35664700 Free PMC article.
-
Association with proteasome determines pathogenic threshold of polyglutamine expansion diseases.Biochem Biophys Res Commun. 2021 Jan 15;536:95-99. doi: 10.1016/j.bbrc.2020.12.065. Epub 2020 Dec 25. Biochem Biophys Res Commun. 2021. PMID: 33370719 Free PMC article.
-
HD and SCA1: Tales from two 30-year journeys since gene discovery.Neuron. 2023 Nov 15;111(22):3517-3530. doi: 10.1016/j.neuron.2023.09.036. Epub 2023 Oct 19. Neuron. 2023. PMID: 37863037 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases